tradingkey.logotradingkey.logo
Discount

Pharmaceuticals

pharmaceuticals

This strategy represents a high-risk, high-reward portfolio. It bypasses traditional large pharmaceutical companies that rely on patent cliffs and stable cash flows, instead investing heavily in emerging biotech firms that own medicines in clinical trials and boast disruptive technologies. The returns from this strategy are driven not by stable drug sales, but by event-driven value re-evaluation resulting from successful clinical data, regulatory approvals, or the launch of blockbuster drugs.

TradingKey SmartPicks
Historical cumulative return+263.58%
Historical annualized return+29.89%
Excess return+12.91%
Sharpe ratio0.68

Historical return chart

--Historical return over the full period
All History
1Y
5Y
All History
This StrategyS&P 500 ETF

Backtest period: 2021-01-04—2026-11-19

Latest updates

--
Action
Security
Change
Watchlist
No Data

Strategy portfolio details

2026.01 (Current)
2026.01 (Current)
No.Name
Recent price (USD)
Date removed
Weight
Sector
Watchlist
No Data

Stock selection logic

The core value of the pharmaceutical industry is shifting from traditional scale expansion to deeper scientific innovation. This pharmaceutical investment strategy avoids large, established drugmakers that rely heavily on their mature drug patents for predictable cash flows. Instead, it focuses on investing in biotech firms at the forefront of clinical research and those possessing disruptive technology platforms. Returns are generated from the release of pivotal clinical data, breakthroughs in regulatory approvals, and the explosive revaluation that accompanies the launch of major new drugs.

01

1. Scalability of Technology Platforms

Goal: Build a long-term innovation moat

We target companies that have more than one single-product offerings and possess advanced technology platforms capable of continuously producing new drug candidates. These platforms should demonstrate applicability across multiple disease classes, enabling the company to construct a diversified Research and Development (R&D) pipeline from a single core technology. This approach looks to significantly reduce the risk of individual project failure while significantly elevating the overall valuation of the R&D pipeline.

02

2. Catalysts in Key Clinical Stages

Goal: Capture non-linear valuation jumps

Value realization in the pharmaceutical sector frequently occurs in discontinuous leaps. We prioritize companies approaching critical clinical milestones—those nearing major data readouts or regulatory decisions. By rigorously evaluating the scientific strength of earlier-stage data, we aim to establish positions ahead of these pivotal events, capturing the sharp valuation premiums driven by positive clinical outcomes and the resulting shift in market expectations.

03

3. Unmet Medical Needs

Goal: Secure monopolistic market pricing power

This strategy targets diseases which have yet to have effective therapies available or where existing treatments have serious limitations.

Related News

China Adds Eli Lilly and Pfizer to Its First Private Insurance List — Is This a Buying Opportunity for Biotech Investors?

TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).

TradingKeyMon, Dec 8
TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).
Eli Lilly vs. Novo Nordisk: Why Lilly Is Better Positioned Under Trump's Drug Pricing Pressure

TradingKey - Eli Lilly and Novo Nordisk, the two dominant players in the US weight-loss drug market, are experiencing vastly different investor sentiment despite facing unprecedented GLP-1 drug price cuts under the Trump administration's price cut initiative.

TradingKeyNov 12, 2025
TradingKey - Eli Lilly and Novo Nordisk, the two dominant players in the US weight-loss drug market, are experiencing vastly different investor sentiment despite facing unprecedented GLP-1 drug price cuts under the Trump administration's price cut initiative.
“Trump’s Pharmacy” Cutting Weight-Loss Drug Prices — What This Means for Novo and Lilly

TradingKey - Following agreements with Pfizer and AstraZeneca, the so-called “twin giants” of weight-loss drugs — Novo Nordisk and Eli Lilly — have now also reached pricing deals with the Trump administration. This marks the latest move in Trump’s broader push to cut U.S. drug prices by up to 90%

TradingKeyNov 7, 2025
TradingKey - Following agreements with Pfizer and AstraZeneca, the so-called “twin giants” of weight-loss drugs — Novo Nordisk and Eli Lilly — have now also reached pricing deals with the Trump administration. This marks the latest move in Trump’s broader push to cut U.S. drug prices by up to 90%
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?

TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.

TradingKeyNov 4, 2025
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.
Lilly, Novo Nordisk Shares Plummet as Trump Announces Price Cut to Ozempic

TradingKey - On Thursday, October 16, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic. As of the time of writing, Eli Lilly (LLY) was down more than 5%, and Novo Nordisk (NVO)

TradingKeyOct 17, 2025
TradingKey - On Thursday, October 16, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic. As of the time of writing, Eli Lilly (LLY) was down more than 5%, and Novo Nordisk (NVO)
Pfizer Bets Big with 110% Premium to Acquire Metsera — A Lifeline in the Weight-Loss Drug Race

As Novo Nordisk and Eli Lilly dominate the weight-loss drug market — building empires from scratch — and after its own R&D setbacks, U.S. pharmaceutical giant Pfizer (PFE) is now going all-in with a doubled-premium acquisition of rising obesity drug developer Metsera.

TradingKeySep 22, 2025
As Novo Nordisk and Eli Lilly dominate the weight-loss drug market — building empires from scratch — and after its own R&D setbacks, U.S. pharmaceutical giant Pfizer (PFE)  is now going all-in with a doubled-premium acquisition of rising obesity drug developer Metsera.
No More Needles? Novo’s Oral Weight-Loss Pill Matches Wegovy Injection for the First Time

TradingKey - Novo Nordisk has released data showing its Wegovy pill achieves weight loss on par with the injection for the first time. Meanwhile, Eli Lilly’s orforglipron, an oral GLP-1 tablet, is expected to gain approval by year-end and launch in 2026 — signaling a potential end to the injection

TradingKeySep 18, 2025
TradingKey - Novo Nordisk has released data showing its Wegovy pill achieves weight loss on par with the injection for the first time. Meanwhile, Eli Lilly’s orforglipron, an oral GLP-1 tablet, is expected to gain approval by year-end and launch in 2026 — signaling a potential end to the injection
Cut to Grow, Novo Nordisk Announces 11% Global Layoffs, Third Profit Forecast Cut This Year

TradingKey - Obesity drug giant Novo Nordisk (NVO.US) announced on Wednesday a major restructuring plan, including 9,000 global job cuts, and delivered its third downward revision to its full-year profit growth guidance in 2025. However, due to its undervalued stock and hopes for cost savings and

TradingKeySep 10, 2025
TradingKey - Obesity drug giant Novo Nordisk (NVO.US) announced on Wednesday a major restructuring plan, including 9,000 global job cuts, and delivered its third downward revision to its full-year profit growth guidance in 2025. However, due to its undervalued stock and hopes for cost savings and

FAQs

Which pharmaceutical company stocks are more likely to lead the weight loss (GLP-1) market in 2026?

By 2026, Eli Lilly and Novo Nordisk remain the undisputed leaders of the global GLP-1 market, each commanding a dominant share through tirzepatide and semaglutide, respectively. 

The major inflection point for 2026 is the emergence of the "oral era": Novo Nordisk's oral semaglutide formulation has achieved full commercial rollout earlier in the year, while Eli Lilly's oral small-molecule candidate orforglipron is advancing toward key regulatory decisions or market entry. Meanwhile, emerging biotech players such as Viking Therapeutics are emerging as serious challengers to the incumbents, with their dual- or multi-target candidate drugs demonstrating strong performance in Phase III trials.

Why are giants like Eli Lilly and Novo Nordisk not included in this pharmaceuticals investment strategy?

Although these two companies dominate the weight-loss space, this strategy is deliberately designed to look explore opportunities outside of mature businesses. Eli Lilly and Novo Nordisk have evolved into mega-cap entities with market capitalizations approaching or exceeding one trillion dollars, and their valuations already fully reflect the bullish market expectations for GLP-1 therapies. 

Valuation saturation: Price movements of these giants are now more heavily influenced by macroeconomic conditions and government pricing policies (such as the negotiated drug prices for 2026 under the Trump administration) than by individual scientific breakthroughs. 

Patent cliff risk: Core patents for Novo Nordisk are beginning to face expiration pressures in certain markets. This strategy seeks non-linear, multi-fold value appreciation and therefore favors mid-cap R&D-focused companies that have not yet been fully priced in by the market and remain on the verge of major clinical inflection points.

What factors can affect the stock price fluctuations of pharmaceutical stocks?

In the 2026 environment, pharmaceutical stock performance is driven by three primary factors:

 Clinical trial results (data catalysts): For R&D-oriented companies, the unblinding of data in pivotal clinical stages—particularly Phase II or III—serves as a make-or-break event that can cause the stock price to double or halve. 

Regulatory and access policies: The U.S. government's implementation of the "Most Favored Nation" (MFN) pricing model and ongoing Medicare drug price negotiations in 2026 have significant implications for profit margins. A company's ability to secure formulary inclusion or leverage new direct-to-consumer (DTC) sales channels is often the decisive factor in commercial success or failure. 

Patent protection and M&A activity: Facing the looming "patent cliff," major pharmaceutical companies exhibit strong M&A appetite in 2026. When small- and mid-cap biotech firms are identified by large players as critical pipeline assets, their share prices frequently receive substantial uplifts from acquisition premiums.

Risk Warning:

The strategies, individual stock research, model portfolios, and update records displayed on this platform do not take into account any user's personal financial circumstances, investment objectives, or risk tolerance. They should not be regarded as personalized investment advice, an assessment of suitability, or trading instructions. Strategy display order, filter results, and labels such as "Spotlight" do not guarantee returns or indicate suitability for any individual.

Past performance does not indicate future results. Backtested and simulated performance does not represent returns from a real account. It is affected by the historical period selected, data quality, model assumptions, and calculation methods, and may be subject to biases such as overfitting. Actual results are also affected by transaction costs, taxes, slippage, liquidity, exchange rate movements, and other factors, and may differ significantly from the results shown.

AI and quantitative models may produce errors or biases, fail to work as intended, and cannot accurately predict market changes. Risk ratings reflect an assessment using a specific method at a particular point in time and do not indicate the maximum possible loss. Investing in securities may result in the loss of part or all of your capital.

Portfolio constituents, model weights, inclusion or removal dates, and reference prices do not represent users' actual holdings, trade execution results, or executable prices. Data and research views may be delayed and may change as markets and models are updated. Adding items to a watchlist is for information tracking only and does not automatically execute trades.

A Pro subscription provides access to the relevant content and features. It does not guarantee the accuracy of research conclusions, the effectiveness of strategies, or any investment returns. Do not make trading decisions solely on the basis of this platform's content. Consult an appropriately qualified professional in your jurisdiction when needed.

tradingkey.logotradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.